https://orcid.org/0000-0002-2508-412X
Figures
Abstract
Background
Scabies is a common skin infestation caused by the Sarcoptes scabei mite. Ivermectin, one of three drugs used in mass drug administration (MDA) for lymphatic filariasis, is also effective for treating scabies. Ivermectin-based MDA was first conducted in Samoa in August 2018, with ivermectin being offered to those aged ≥5 years. Here, we report scabies prevalence in Samoa after MDA.
Methods
We conducted household surveys 1.5–3.5 months (Survey 1) and 6–8 months (Survey 2) after the 2018 MDA in 35 primary sampling units. We conducted clinical examination for scabies-like rash and used International Alliance for the Control of Scabies classification criteria. We estimated scabies prevalence by age, gender and region. Multivariable logistic regression was used to assess factors associated with prevalence.
Results
We surveyed 2868 people (499 households) and 2796 people (544 households) aged 0–75 years in Surveys 1 and 2, respectively. Scabies prevalence increased from 2.4% (95% CI 2.1–2.7%) to 4.4% (95% CI 4.0–4.9%) between surveys. Scabies was associated with younger age (0–4 years: aOR 3.5 [2.9–4.2]; 5–15 years: aOR 1.6 [1.4–1.8] compared to ≥16 years), female gender (aOR 1.2 [95% CI 1.1–1.4]; region (aOR range from 1.4 [1.1–1.7] to 2.5 [2.1–3.1] between regions), large households (aOR 2.6 [2.0–3.4] households ≥13), and not taking MDA in 2018 (aOR 1.3 [95% CI 1.1–1.6]).
Author summary
Scabies is a common skin disease that is caused by a small mite that burrows into the skin. It can be treated by a drug called ivermectin, which was given to every person aged 5 years and over in Samoa in 2018 to treat a different disease, known as lymphatic filariasis. We wanted to understand how common scabies was in the people of Samoa and so did two surveys where we visited people’s houses that we randomly selected. We asked people in each household questions about scabies symptoms and looked at their skin for signs of scabies. We surveyed 2868 people in 499 households in the first survey and 2796 in 544 households in the second survey. We found that 2.4% of people in the first survey and 4.4% of people in the second survey had scabies. We also found that some people were more likely to have scabies: younger children, women, people living in some regions of Samoa, people living with more people in their household, and people who didn’t take the medicine for lymphatic filariasis in 2018.
Citation: Willis GA, Kearns T, Mayfield HJ, Sheridan S, Thomsen R, Naseri T, et al. (2023) Scabies prevalence after ivermectin-based mass drug administration for lymphatic filariasis, Samoa 2018–2019. PLoS Negl Trop Dis 17(8): e0011549. https://doi.org/10.1371/journal.pntd.0011549
Editor: Kosta Y. Mumcuoglu, Hebrew University Hadassah Medical School, ISRAEL
Received: December 22, 2022; Accepted: July 24, 2023; Published: August 22, 2023
Copyright: © 2023 Willis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper. We are unable to provide individual-level prevalence data and demographic data because of the potential for breaching participant confidentiality. The communities in Samoa are very small, and individual-level data such as age, sex, and village of residence could potentially be used to identify specific persons. For researchers who meet the criteria for access to confidential data, the data are available on request from the Human Ethics Officer at the Australian National University Human Research Ethics Committee, email: human.ethics.officer@anu.edu.au.
Funding: This work received financial support from the Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD), which is funded at The Task Force for Global Health primarily by the Bill & Melinda Gates Foundation, the United Kingdom Department for International Development, and the United States Agency for International Development through its Neglected Tropical Diseases Program. C.L.L. was funded by Australian National Health and Medical Research Council Fellowships (APP1109035 and APP1158469). ACS is funded by a Viertel Senior Medical Research Fellowship and a National Health and Medical Research Council Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was supported in whole or in part, by the Bill & Melinda Gates Foundation [Grant Number OPP1053230]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. DE was funded by a National Health and Medical Research Council Fellowship.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Scabies is a common neglected tropical disease, with up to 450 million incident cases per year globally, with the highest prevalence in the Pacific Islands and Latin America [1–3]. Scabies is caused by infestation with the microscopic mite Sarcoptes scabiei var. hominis and is predominantly transmitted through close personal contact [4]. The mite burrows into the skin and consumes the epidermis and sera, triggering an immune response causing rash and intense itching [5]. Cases are asymptomatic in the first four to six weeks after initial infestation, and most cases are diagnosed clinically when they present with rash and itching [6–8]. Scabies affects all age groups but is more common in children and in low- and middle-income countries [2]. Overcrowding is a driver of transmission, and institutional outbreaks occur in settings such as schools, prisons, aged care facilities, and hospitals [2].
Itching from scabies can be debilitating, and the direct effects on the skin lead to 0.21% of disability-adjusted life-years worldwide [9]. Additionally, scabies lesions can become secondarily infected with Streptococcus pyogenes and/or Staphylococcus aureus [4,10,11], and potentially result in a substantial disease burden. S. pyogenes pyoderma has been associated with acute post-streptococcal glomerulonephritis [4,12] and there is evidence to suggest an association with acute rheumatic fever [13,14].
Mass drug administration (MDA) with ivermectin has been shown to effectively reduce scabies in several studies, with varying success in sustaining reduction in prevalence [3,15–18]. Trials from Pacific Island countries with very high scabies prevalence have shown a 90% reduction in scabies using ivermectin-based MDA. In these trials, oral ivermectin was given to most of the population, and topical permethrin to groups where ivermectin is currently contra-indicated [17,19]. Reductions in scabies prevalence were sustained for 24 and 36 months respectively [20,21]. However, other studies from Tanzania and northern Australia, with lower baseline prevalence, did not demonstrate a sustained reduction [15,22]. However, a difference in the drug regimen may have influenced findings in the Tanzanian study, with only one dose of ivermectin being given annually and those under 5 years of age being offered benzyl benzoate cream [22], while a high proportion of new entries to the cohort was thought to have influenced findings in the Australian study [15].
Recently, a framework for scabies control was developed after an informal WHO consultation [23]. The framework recommended that where prevalence is 10% or above, two doses of ivermectin-based MDA given 7–14 days apart can be considered as a method for public health control. Three to five annual rounds are proposed, with a minimum coverage target of 80% of the population [23].
Despite the high global burden of scabies, global prevalence estimates have largely been based on modelling studies, with limited robust data from surveillance systems or field surveys [23,24]. In the Western Pacific region, school-based and household surveys from several countries, including Samoa, have reported high prevalence [25–28]. In Samoa, a survey in 1997 found scabies prevalence of 4.9% (95% confidence interval [CI] 3.0–7.0%) [29]; the authors raised the possibility that the lower than expected prevalence might be the result of ivermectin-containing MDA, which was used for lymphatic filariasis control in Samoa in 1996 and 1997 [30]. In February 2018, a school-based survey conducted in Samoa (localised areas in the southern parts of Upolu island) found scabies prevalence of 14.4% among children aged 4–15 years [28]. In neighbouring American Samoa, a review of medical records in 2011–2012 estimated an annual incidence of presentation with scabies of 29.3 per 1,000 among children aged ≤14 years (99.9 per 1,000 in children aged less than one year), with bacterial superinfection in 53% of cases [31].
In August 2018, the Samoa Ministry of Health implemented the first round of MDA for lymphatic filariasis using three drugs (ivermectin, diethylcarbamazine, and albendazole) for eligible adults and children aged ≥5 years, while children aged 2–4 years were offered diethylcarbamazine and albendazole only [32]. In this paper, we report on scabies prevalence in Samoa in two population representative surveys of all ages conducted within an eight month period after the 2018 MDA, and we investigated risk factors for infection.
Methods
Background and setting
Samoa is an independent country in the South Pacific with a population of approximately 200,000 [33]. Most of the population live on the two main islands of Upolu (where the capital city, Apia, is located) and Savai’i. Samoa is divided into four administrative regions: Apia Urban Area (20% of population), Northwest Upolu (35% of population), Rest of Upolu (23% of population), and Savai’i (22% of population). There are approximately 338 villages, with an average population of 580 (range <20 to 4300) per village [34].
The Surveillance and Monitoring to Eliminate Lymphatic Filariasis and Scabies (SaMELFS) study in Samoa was conducted with the primary aim of assessing the impact of MDA on lymphatic filariasis and scabies [32,35,36]. Due to logistic reasons, the first survey was delayed and took place 1.5 to 3.5 months after MDA (September to November 2018, henceforth “Survey 1”), instead of prior to MDA as intended. The second survey was conducted 6 to 8 months after the MDA (March to May 2019, henceforth “Survey 2”). The SaMELFS surveys presented an opportunity to assess scabies prevalence in all age groups in the months following nationwide ivermectin-based MDA.
Ethics
Ethical approval was obtained from human research ethics committees at the Samoa Ministry of Health and The Australian National University (protocol 2018/341). The study was conducted in collaboration with the Samoa Department of Health, World Health Organization Samoa country office, Samoa Red Cross, and The Task Force for Global Health. Written informed consent was obtained from all participants, or parent/guardian in the case of minors aged <18 years.
Study design
Detailed description of the sampling design has been previously reported [35,37]. In brief, participants were surveyed from 35 primary sampling units (PSUs) across Upolu, Savai’i, and Manono Islands. Each PSU consisted of one large or two smaller villages, and a total of 43 individual villages were included. Fifteen households were selected from each PSU, and household members of all ages were invited to participate in the scabies survey. If nobody was home at the time of the visit, the house was revisited later in the day and/or on another day. If household members were still absent at the second attempt and the target sample size had not yet been met, the household was replaced with the nearest inhabited household. The same PSUs were selected for both surveys. Households were selected independently for each survey, and by chance, a small number of households were included in both surveys. For lymphatic filariasis, convenience surveys of children aged 5–9 years were also conducted outside of the home, e.g., at schools and community centres. However, scabies examination was not conducted during convenience surveys because of privacy reasons.
Sample size calculation
A target sample size of 2000 people in each age group (5–9 years, and ≥10 years) was required to detect a critical threshold of 2% filarial antigen prevalence, with a 5% chance of type 1 error, 75% power (when true prevalence is 1%), a design effect of 2.0, and correcting for the finite population [35]. Scabies prevalence was anticipated to be approximately 10%, so the above samples size was assumed to be adequate for estimating prevalence. Household members of all ages (including those aged <5 years) were invited to participate in the scabies survey.
Training of field teams
A five-day training program (including two days of pilot village surveys) was conducted before each survey and included didactic and practical sessions on study background and rationale, field logistics, obtaining informed consent, and field data collection using smartphones. Field teams were trained in clinical examination for scabies based on training programs used in other studies [38,39], and provided with pictorial flipcharts to use during surveys. The lead trainer was an Australian nurse with experience in scabies field surveys (TK) and was available through both surveys to assist field teams. The same training methods and materials were used prior to both surveys.
Field team members consisted of community workers from the Samoa Red Cross, staff from the Ministry of Health, Samoan student nurses (2019), and Australian researchers (nurse, doctors, epidemiologists). Each field team included at least one clinician (nurse or student nurse), with remote support by the Australian nurse or doctors when required, including telephone discussion and review of de-identified photographs of rashes. Some team members participated in both surveys.
Enrolment
We contacted community leaders (mayors, pastors, chiefs) in each village to discuss the survey and arrange suitable dates and times for the field team to visit and followed up with a hand delivered letters to confirm details. The village leaders informed the households about the timing and purpose of the survey. On the day of the survey, households were approached by a Samoan team member to obtain verbal consent to discuss survey participation with the family. If the head of the household agreed to participate, individual written informed consent was obtained from those eligible. An individual was eligible to participate if the selected house was their primary place of residence, and/or if they slept there the previous night.
Data collection
Questionnaire and clinical examination data were collected electronically using Secure Data Kit software (www.securedatakit.com, now Standard Data) on smartphones, and electronic records were uploaded and stored on a SQL secure cloud-based server. Each participant was assigned a unique scannable QR code to link their enrolment/consent form, questionnaires, and blood samples.
Questionnaires
Questionnaire data were collected through interviews with participants or their parent/guardian. Interviews were conducted in Samoan or English, depending on the participant’s preference. Questions included information on demographics, occupation, number of household members, and participation in the 2018 MDA. Scabies-specific questions included skin itching, scratching, or scabies-like rash experienced by the participants, their household members, and close contacts (other family, friends, classmates).
Clinical examination for scabies
Exposed skin on arms and legs was examined to identify the presence and distribution of scabies-like lesions. In children, the abdomen, back and chest were also examined. The field teams recorded data on the rash appearance (typical scabies, atypical scabies, or other rash), and distribution of the lesions.
Scabies classification and definitions
Scabies was defined using three categories within the International Alliance for the Control of Scabies (IACS) Criteria (Table 1) [40]. Classification was completed during data analysis into the following categories: no scabies, B3, C1, C2, and ‘any scabies’ (combination of B3, C1 and C2).
Data analysis
Data analysis was conducted using Stata version 15 (Statacorp 2017). Descriptive analyses were used to report the demographic characteristics of participants. Crude scabies prevalence by year, region, age groups, and gender were calculated, and the Clopper-Pearson binomial method was used to estimate 95% confidence intervals (CI). Prevalence estimates were adjusted for survey design using Stata command svyset (adjusting for probability of PSU selection within the country, probability of household selection within PSU, clustering at PSU and household, and finite population correction over all PSUs and households; standard errors were calculated using Taylor-linearised variance estimation). Prevalence estimates (using Stata command proportion) were standardised for age (5-year age groups from Samoa 2016 census) and gender.
Using ‘any scabies’ as the outcome measure, multivariable logistic regression (Stata command svy:logistic) was used to estimate odds ratios for covariates, including year, region, age group, gender, number of household members (as a proxy for crowding), at least one employed person in the household (as a proxy for socioeconomic status) and participation in 2018 MDA. Covariates that were significant at p<0.2 in univariable analysis were included in the final multivariable model. The intracluster correlation coefficient (ICC) was calculated using mixed-effects logistic regression (Stata commands melogit and estat icc) to provide a measure of how similar observations were within PSUs and households. Statistical significance was defined as p<0.05.
Results
Participants
At Survey 1, 2868 participants from 499 households were examined for scabies (median 5 persons per household, range 1–31). Survey 2 included a similar number of participants from the same PSUs (2796 participants from 544 households, median four persons per household, range 1–21). The number of participants by age group differed between the two surveys due to lower number of participants aged <5 years at Survey 2, however, the median age was similar between surveys (Table 2). There was no difference in gender distribution between the two surveys, nor the proportion of those aged ≥5 years who recalled taking MDA in 2018. In both surveys, almost all participants were born in Samoa (99%) and participants were similarly distributed between the four regions.
Scabies prevalence, and comparison between Survey 1 and 2
According to IACS classifications, 74 (2.6%, 95% CI 2.0–3.2%) and 103 (3.7%, 95% CI 3.0–4.5%) participants were diagnosed with scabies (B3, C1 or C2) in Survey 1 and Survey 2, respectively. Most of the cases identified were clinical scabies (B3). Scabies-like lesions (typical or atypical) were identified in 93 participants (3.2%, 95% CI 2.6–3.9%) in Survey 1, and 133 participants (4.8%, 95% CI 4.0–57%) in Survey 2 (Table 3). In Surveys 1 and 2, 81.0% and 75.2% of rashes were in a typical distribution for scabies, respectively. In Survey 1, 82.8% and 76.3% reported itch and positive contact history features, respectively, while in survey 2, 75.2% and 24.8% reported these features, respectively.
After adjusting for survey design and standardizing for age and gender, scabies prevalence was higher in Survey 2 (4.4%, 95% CI 4.0–4.9%) than in Survey 1 (2.4%, 95% CI 2.1–2.7%) (Table 4 and Fig 1), with a greater increase among females than males. Age-specific prevalence was highest among those aged 0–4 years, and higher in Survey 2 than Survey 1 for all age groups (Table 4 and Fig 1). In participants aged 0–4 years, adjusted prevalence of clinical scabies (B3) was higher in Survey 2 (7.3%, 95% CI 6.2–8.4%) than Survey 1 (3.5%, 95% CI 2.9–4.4%), but not significantly different for suspected scabies (C1 or C2). In those aged ≥16 years, clinical scabies (B3) was also more common in Survey 2 (3.0%, 95% CI 2.5–3.4%) than Survey 1 (1.2%, 95% CI 1.0–1.5%). Scabies prevalence by diagnostic category and age group for Surveys 1 and 2 are provided in S1 Table.
Prevalence estimates adjusted for survey design. Prevalence for ‘all ages’ standardised for age and gender, and results for age groups standardised for gender.
Adjusted prevalence for all ages was higher in Survey 2 than in Survey 1 for three of the four regions, and the difference was statistically significant for Apia Urban Area and North-West Upolu (Fig 2). There was a statistically significant increase in scabies prevalence between the surveys in the following age- and region-specific groups: 0–4 years and ≥16 years in Apia Urban Area; 5–15 years and ≥16 years in North-West Upolu; ≥16 years in Rest of Upolu; and 0–4 years in Savai’i (Fig 2).
a) Apia Urban Area, b) North West Upolu, c) Rest of Upolu, and d) Savai’i. Prevalence estimates adjusted for survey design and standardised for age and gender. (*Results not reported for participants aged 0–4 years in Rest of Upolu in Survey 2 because <5 participants were screened in this subgroup).
Clustering of scabies at PSU and household levels
There was evidence of clustering of scabies at the PSU level (ICC 0.53 and 0.32 in Surveys 1 and 2, respectively). Scabies prevalence by PSU for Surveys 1 and 2 are shown in S2 Table.
Clustering at the household level was more intense than at the PSU level (ICC 0.70 and 0.49 in Surveys 1 and 2, respectively).
Risk factors for scabies
Among participants of all ages, after adjusting for Survey 1 or 2, region, household size, gender, age groups, at least one employed person screened at the household, participation in 2018 MDA, and survey design, significant risk factors for scabies were: surveyed in survey 2 (adjusted odds ratio [aOR] 2.1 (1.9–2.4); female gender (aOR 1.2 [95% CI 1.1–1.4]; age <16 years (aOR 3.4 [95% CI 2.9–4.2] for 0–4 years, and aOR 1.6 [95% CI 1.4–1.8] for 5–15 years compared to those aged ≥16 years); living in a large household (13 or more residents in household, aOR 2.6 [95% CI 2.0–3.4] compared to households with 1–4 residents); not taking MDA in 2018 (aOR 1.3 [95% CI 1.1–1.6]); and living in a region other than Savai’i, with the highest risk in Apia Urban Area (aOR 2.5, 95% 2.1–3.1) (Table 5). Findings were similar when only participants aged ≥5 years were included in the model (i.e., those eligible for ivermectin in 2018 MDA) (S3 Table).
Discussion
Our study found moderate prevalence (2.4% and 4.4%) of scabies among two population-representative surveys of all age groups in Samoa conducted within eight months of the 2018 ivermectin-based MDA for lymphatic filariasis. We found regional differences in scabies prevalence, and risk factors for infection, including young age (<16 years), female gender, and living in large households. Among those aged ≥5 years, non-participation in the MDA in 2018 was associated with higher scabies prevalence.
The overall prevalence of 2.4% and 4.4% in our two surveys were below the currently recommended threshold of 10% community prevalence for starting MDA for scabies [23,41]. Where the prevalence is moderate (2-<10%) the recommendations are less clear, due to lack of evidence. Our findings are similar those from a survey conducted in 1999 among Samoan children aged 5–17 years where scabies prevalence was 4.9% [29]; notably two rounds of ivermectin-containing MDA were distributed in 1996 and 1997 [30]. Our results were considerably lower than the 14.4% prevalence identified in a school-based survey of 4–15 year-olds conducted by Taiaroa et al in February 2018, but this study was limited to a few small communities in southern Upolu [28]. While the 2018 study was conducted prior to MDA, we were not able to use the results as a pre-MDA baseline because the survey was not nationally representative, and there may be considerable variation in scabies prevalence between regions and communities. Furthermore, Taiaroa et al used a different case definition for scabies that did not include a history of itch or household contacts with itch [28].
We found higher scabies prevalence in Survey 2 (6–8 months post-MDA) than in Survey 1 (1.5–3.5 months post-MDA). Overall prevalence in all age groups increased from 2.4% (95% CI 2.1–2.7%) to 4.4% (95% CI 4.0–4.9%). The greatest increase was observed among those aged under 5 years, from 6.5% (95% CI 5.6–7.5%) to 11.1% (9.3–13.1%), with most of the increase observed in category B3 (clinical scabies). While the increase in prevalence was statistically significant, the public health significance of this finding is unclear. The results were difficult to interpret because baseline prevalence immediately before MDA was not available and increase in prevalence could have been due to natural fluctuation in prevalence or random error. However, it is possible that this may represent reinfestation, particularly as young children <5 years of age were not treated with ivermectin and only one round of ivermectin-based MDA was distributed in Samoa prior to our surveys, less than the three to five rounds of annual ivermectin-based MDA recommended for scabies [23,41].
Our study identified highest prevalence among those aged under 5 years, who were not given ivermectin during the 2018 MDA. We also found higher prevalence in females, possibly because of closer and more frequent contact with young children through caring duties such as feeding and carrying. Higher prevalence among households with more residents is consistent with the general understanding that crowding is a risk factor for infestation [31]. More intense clustering of scabies at the household level compared to community level suggests the importance of transmission between household members. Among those aged over 5 years, higher prevalence in those who did not take MDA in 2018 (after adjusting for age, sex, and household size) suggests that ivermectin may have been effective in reducing prevalence, but other factors may be at play. A recent community-based trial in Fiji found that one dose of ivermectin-based MDA (with topical permethrin to contraindicated groups) was highly effective at reducing scabies prevalence (from 15.2% to 2.7% over 12 months) and non-inferior to two doses [42], but we were unable to assess the impact of ivermectin-containing MDA in Samoa because of the absence of a baseline assessment. The reasons for regional differences in scabies prevalence in Samoa are unclear, but notably the two regions with significantly higher overall prevalence in Survey 2 than Survey 1 (Apia Urban Area and North West Upolu) are the most densely populated, and also reported lower MDA coverage rates in 2018 than the other regions [32].
Our study has several limitations, perhaps the most significant being the absence of a baseline (pre-MDA) survey making interpretation of results challenging. As the survey methods were designed for the primary objectives relating to lymphatic filariasis, our surveys included a relatively low number of children aged under five years (479 in Survey 1 and 188 in Survey 2), potentially affecting the generalisability of the findings. Our proxy measure for socioeconomic status (at least one employed person screened in household) did not account for employed persons who were not home during the survey, or those who may have declined to participate. Impetigo data were not collected as we were measuring the indirect impact of LF ivermectin MDA on scabies prevalence.
Measurement bias may also have occurred as scabies examinations were mostly conducted by field workers who had limited clinical experience in scabies diagnosis. Despite supervision and remote support, this may have led to some misclassification. Additionally, different field teams between the two surveys might also have contributed to differences in results between years, but this issue was minimised by using the same training methods and materials immediately prior to each survey. In addition, it is likely the design effect was underestimated in our calculation of the study’s required sample size based on sample ICCs, therefore reducing the study’s effective sample size and reducing the study’s power. However, the impact of this underestimation does not appear to have had a substantial impact on precision estimates, as confidence intervals reported in Tables 3–5 or Figs 1 and 2 appear not to be unduly wide. Longer term follow-up surveys were planned but have been delayed because of prolonged border closures related to COVID-19 pandemic.
Despite the limitations, our study provides the largest population representative household survey of scabies in Samoa and one of the largest population surveys of scabies in the Pacific Islands. To minimise errors related to classifying scabies into IACS categories during fieldwork, we only asked field teams to record clinical observations (rash, distribution, number), and classifications were done during the data analysis phase. This approach greatly simplified fieldwork activities and should be considered during field surveys when clinical experts are not readily available.
Based on our results, ongoing surveillance is recommended for monitoring scabies prevalence in Samoa. Further increases in prevalence may justify targeted control strategies for scabies. Considering that scabies prevalence was highest among young children, more intensive surveillance in this age group may be warranted, potentially integrated with childhood programs (e.g., immunisation visits, well baby clinics) or school health team visits. Integration with other public health surveillance programs (e.g., for lymphatic filariasis and other neglected tropical diseases) would improve cost-effectiveness and long-term sustainability.
Supporting information
S1 Table. Crude and adjusted prevalence of scabies by age group and International Alliance for the Control of Scabies (IACS) classifications (41), Samoa, Surveys 1 and 2.
https://doi.org/10.1371/journal.pntd.0011549.s001
(PDF)
S2 Table. Crude and adjusted prevalence of scabies by PSU, Samoa, Surveys 1 and 2.
https://doi.org/10.1371/journal.pntd.0011549.s002
(PDF)
S3 Table. Crude (univariate model) and adjusted (multivariable model) odds ratios for scabies prevalence (IACS B3, C1 and C2 classifications combined) in participants aged ≥5 years (eligible for ivermectin in 2018 MDA), Samoa, Surveys 1 and 2.
https://doi.org/10.1371/journal.pntd.0011549.s003
(PDF)
Acknowledgments
We would like to thank all the staff at the Samoa Ministry of Health who supported the many different aspects of the study. We especially thank Miriama Asoiva who provided valuable advice on local logistics and cultural sensitivities, and assistance with obtaining permissions to conduct village visits. We also thank Fuatai Maiava for making it possible for nurses to assist with the household surveys.
We sincerely thank Tautala Maula, the general secretary of the Samoa Red Cross, and her team (especially Babey Suniula, Nixon Mataia, Brenda Koon Wai You, Alesi Mataia, and Shem Lepale) for their enthusiastic and untiring support with fieldwork, village visits, and laboratory work; this survey would not have been possible without their hard work and dedication.
We greatly appreciate all the support and advice provided by Rasul Baghirov and Lepaitai Hansell at the WHO country office in Samoa, and thank them for generously sharing their wisdom. We also thank the Australian volunteers and students who assisted with fieldwork and data management (Brady McPherson, Kelley Meder, Meru Sheel, Benjamin Dickson, Kinley Wangdi, Sophie Phelan, Ximena Tolosa).
References
- 1. Engelman D, Cantey PT, Marks M, Solomon AW, Chang AY, Chosidow O, et al. The public health control of scabies: priorities for research and action. Lancet (London, England). 2019;394(10192):81–92. pmid:31178154
- 2. Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo worldwide: a systematic review. The Lancet Infectious Diseases. 2015;15(8):960–7. pmid:26088526
- 3. Lake SJ, Kaldor JM, Hardy M, Engelman D, Steer AC, Romani L. Mass drug administration for the control of scabies: a systematic review and meta-analysis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2022. pmid:35088849
- 4. Heukelbach J, Feldmeier H. Scabies. Lancet 2006;367(9524):1767–74. pmid:16731272
- 5. Walton S, Currie B. Problems in diagnosing scabies, a global disease in human and animal populations. Clinical Microbiology Reviews. 2007;20(2):268–79. pmid:17428886
- 6. Jackson A, Heukelbach J, Filho A, Júnior Ede B, Feldmeier H. Clinical features and associated morbidity of scabies in a ruralcommunity in Alagoas, Brazil. Tropical Medicine and International Health. 2007;12(4):493–502. pmid:17445140
- 7. Burkhart CG, Burkhart CN, Burkhart KM. An epidemiologic and therapeutic reassessment of scabies. Cutis; Cutaneous Medicine For The Practitioner. 2000;65(4):233–40.
- 8. Jimenez-Lucho VE, Fallon F, Caputo C, Ramsey K. Role of prolonged surveillance in the eradication of nosocomial scabies in an extended care veterans affairs medical center. American Journal of Infection Control. 1995;23(1):44–9. pmid:7762874
- 9. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). 2016;388(10053):1545–602. pmid:27733282
- 10. Currie B, Carapetis J. Skin infections and infestations in Aboriginal communities in northern Australia. Australasian Journal of Dermatology. 2000;41(3):139–45. pmid:10954983
- 11. Tong SYC, Andrews RM, Kearns T, Gundjirryirr R, McDonald MI, Currie BJ, et al. Trimethoprim-sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: A pilot randomised controlled trial. Journal of Paediatrics and Child Health. 2010;46(3):131–3.
- 12. Kearns T, Evans C, Krause V. Outbreak of Acute Post Streptococcal Glomerulonephritis in the Northern Territory—2000. The Northern Territory Disease Control Bulletin. 2001;8(2):6–14.
- 13. Oliver J, Bennett J, Thomas S, et al. Preceding group A streptococcus skin and throat infections are individually associated with acute rheumatic fever: evidence from New Zealand. BMJ Glob Health 2021; 6(12).
- 14. O’Sullivan L, Moreland NJ, Webb RH, Upton A, Wilson NJ. Acute Rheumatic Fever After Group A Streptococcus Pyoderma and Group G Streptococcus Pharyngitis. The Pediatric infectious disease journal. 2017;36(7):692–4. pmid:28121967
- 15. Kearns TM, Speare R, Cheng AC, McCarthy J, Carapetis JR, Holt DC, et al. Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community. PLoS neglected tropical diseases. 2015;9(10):e0004151. pmid:26516764
- 16. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, Wate C, et al. Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bull World Health Organ. 2005;83(1):34–42. pmid:15682247
- 17. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, et al. Mass Drug Administration for Scabies Control in a Population with Endemic Disease. New England Journal of Medicine. 2015;373(24):2305–13. pmid:26650152
- 18. Marks M, Toloka H, Baker C, Kositz C, Asugeni J, Puiahi E, et al. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2019;68(6):927–33.
- 19. Romani L, Marks M, Sokana O, Nasi T, Kamoriki B, Cordell B, et al. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect Dis. 2019;19(5):510–8. pmid:30956111
- 20. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, et al. Mass Drug Administration for Scabies—2 Years of Follow-up. N Engl J Med. 2019;381(2):186–7. pmid:31242358
- 21. Marks M, Romani L, Sokana O, Neko L, Harrington R, Nasi T, et al. Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;70(8):1591–5.
- 22. Martin D, Wiegand R, Goodhew B, Lammie P, Mkocha H, Kasubi M. Impact of Ivermectin Mass Drug Administration for Lymphatic Filariasis on Scabies in Eight Villages in Kongwa District, Tanzania. The American journal of tropical medicine and hygiene. 2018;99(4):937–9. pmid:30062986
- 23. Engelman D, Marks M, Steer AC, Beshah A, Biswas G, Chosidow O, et al. A framework for scabies control. PLoS neglected tropical diseases. 2021;15(9):e0009661. pmid:34473725
- 24. Cox V, Fuller LC, Engelman D, Steer A, Hay RJ. Estimating the global burden of scabies: what else do we need? Br J Dermatol. 2021;184(2):237–42. pmid:32358799
- 25. Mason DS, Marks M, Sokana O, Solomon AW, Mabey DC, Romani L, et al. The Prevalence of Scabies and Impetigo in the Solomon Islands: A Population-Based Survey. PLoS neglected tropical diseases. 2016;10(6):e0004803. pmid:27348119
- 26. Osti MH, Sokana O, Phelan S, Marks M, Whitfeld MJ, Gorae C, et al. Prevalence of scabies and impetigo in the Solomon Islands: a school survey. BMC Infect Dis. 2019;19(1):803. pmid:31519153
- 27. Romani L, Koroivueta J, Steer AC, Kama M, Kaldor JM, Wand H, et al. Scabies and impetigo prevalence and risk factors in Fiji: a national survey. PLoS neglected tropical diseases. 2015;9(3):e0003452. pmid:25738499
- 28. Taiaroa G, Matalavea B, Tafuna’I M, Lacey JA, Price DJ, Isaia L, et al. Scabies and impetigo in Samoa: A school-based clinical and molecular epidemiological study. The Lancet Regional Health—Western Pacific. 2021;6:100081. pmid:34327410
- 29. Steer AC, Adams J, Carlin J, Nolan T, Shann F. Rheumatic heart disease in school children in Samoa. Arch Dis Child. 1999;81(4):372. pmid:10577365
- 30. Ichimori K, Tupuimalagi-Toelupe P, Iosia VT, Graves PM. Wuchereria bancrofti Filariasis Control in Samoa before PacELF (Pacific Programme to Eliminate Lymphatic Filariasis). Tropical Medicine and Health. 2007;35(3):261–9.
- 31. Feldmeier H, Heukelbach J. Epidermal parasitic skin diseases: a neglected category of poverty-assocaited plagues. Bull World Health Organ. 2009; 87(2):152–159
- 32. Willis GA, Mayfield HJ, Kearns T, Naseri T, Thomsen R, Gass K, et al. A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018. PLoS neglected tropical diseases. 2020;14(11):e0008854. pmid:33253148
- 33. Samoa Bureau of Statistics. 2016 Census projection Apia: SBS; 2018 [cited 2019 Jul 18]. Available from: http://www.sbs.gov.ws/digi/6-2016%20Census%20Projection.xlsx.
- 34.
Samoa Bureau of Statistics. 2016 Census [Internet]. Apia: SBS; 2018 [cited 2019 Jul 17]. Available from: https://www.sbs.gov.ws/population-and-demography.
- 35. Lau CL, Meder K, Mayfield HJ, Kearns T, McPherson B, Naseri T, et al. Lymphatic filariasis epidemiology in Samoa in 2018: Geographic clustering and higher antigen prevalence in older age groups. PLoS neglected tropical diseases. 2020;14(12):e0008927. pmid:33347456
- 36. Mayfield HJ, Sturrock H, Arnold BF, Andrade-Pacheco R, Kearns T, Graves P, et al. Supporting elimination of lymphatic filariasis in Samoa by predicting locations of residual infection using machine learning and geostatistics. Sci Rep. 2020;10(1):20570. pmid:33239779
- 37. McPherson B, Mayfield HJ, McLure A, Gass K, Naseri T, Thomsen R, et al. Evaluating Molecular Xenomonitoring as a Tool for Lymphatic Filariasis Surveillance in Samoa, 2018–2019. Trop Med Infect Dis. 2022;7(8). pmid:36006295
- 38. Osti MH, Sokana O, Gorae C, Whitfeld MJ, Steer AC, Engelman D. The diagnosis of scabies by non-expert examiners: A study of diagnostic accuracy. PLoS neglected tropical diseases. 2019;13(8):e0007635. pmid:31425513
- 39. Shield JM, Kearns TM, Gar enggulkpuy J, Walpulay L, Gundjirryirr R, Bundhala L, et al. Cross-Cultural, Aboriginal Language, Discovery Education for Health Literacy and Informed Consent in a Remote Aboriginal Community in the Northern Territory, Australia. Trop Med Infect Dis. 2018;3(1).
- 40. Engelman D, Yoshizumi J, Hay RJ, Osti M, Micali G, Norton S, et al. The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies. Br J Dermatol. 2020;183(5):808–20. pmid:32034956
- 41. World Health Organization Regional Office for the Western Pacific. WHO Informal Consultation on a Framework for Scabies Control. Meeting Report.; 2019.
- 42. Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, et al. Community control strategies for scabies: A cluster randomised noninferiority trial. PLoS Med. 2021;18(11):e1003849. pmid:34758017